Peter J. Weiler joins Edesa Biotech as CFO on May 1, 2025, bringing extensive leadership in biotechnology and pharmaceuticals. Weiler's experience includes roles as President of Exzell Pharma and VP…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, to lead financial strategy in developing therapies for immuno-inflammatory diseases. Stephen Lemieux transitions to…
AmplifyBio, a promising biotech company based in central Ohio, has closed its operations, despite its ambitious beginnings and significant investments. Founded in 2021 as a gene therapy offshoot from Battelle,…
The biotech sector faced significant challenges, causing stocks like Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics to plummet. Biohaven's stock decreased by 35.3% due to disappointing results from its bipolar disorder…
The biotech and pharmaceutical industries face significant layoffs due to shifting priorities, financial challenges, and strategic realignments. Major companies like Nkarta, ElevateBio, Alector, and others are reducing their workforce to…
Small and mid-size biotech firms compete with larger companies by innovating life-altering treatments amid complex challenges. IDDI, a clinical research organization, supports smaller firms by offering precision-guided trial designs and…
The biotech and pharmaceutical industries are undergoing strategic realignments, leading to layoffs as companies refocus on core objectives. Nkarta and Atea Pharmaceuticals have significantly reduced their workforce, emphasizing key therapeutic…
Biotech and pharma companies are undergoing significant workforce reductions to align strategic priorities with economic constraints. Key companies involved include Nkarta, ElevateBio, Atea Pharmaceuticals, Vaxart, and TC BioPharm. The focus…
Biotechnology innovation drives new therapies, with small and mid-size pharma firms playing a key role despite the challenges posed by larger companies and complex regulations. The global biotechnology market is…
A significant restructuring is occurring within the U.S. FDA and HHS, affecting thousands of positions and raising concerns about the future of innovative medicine in America. Peter Marks, former director…